Journal
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
Volume 9, Issue 7, Pages 406-417Publisher
NATURE PORTFOLIO
DOI: 10.1038/nrgastro.2012.101
Keywords
-
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare, Government of Japan
- Grants-in-Aid for Scientific Research [24659368, 22590737] Funding Source: KAKEN
Ask authors/readers for more resources
The IL28B locus attracted the attention of HCV researchers after a series of genome-wide association studies independently identified a strong association between common IL28B polymorphisms and the outcome of PEG-IFN-alpha plus ribavirin combination therapy in patients chronically infected with HCV genotype 1. This association was subsequently replicated for other HCV genotypes and has been linked to spontaneous eradication of HCV, development of steatosis and biochemical changes (such as altered levels of.-glutamyl transpeptidase and LDL). Despite the introduction of direct-acting antiviral drugs, IL28B genetics are likely to play a part in patient selection and treatment decisions-moving towards a personalized approach to therapy. In HCV-infected patients with the so-called favourable IL28B genotype (rs12979860 CC; associated with better treatment response), hepatic expression levels of IL28B and interferon-stimulated genes seem to be reduced at baseline, but are induced more strongly after IFN-alpha administration, perhaps resulting in more effective elimination of the virus. Clarification of the mechanisms underlying these biological phenomena will lead to improved understanding of the antiviral effects of IFN-lambda and, ideally, to the development of better therapies against HCV infection. This Review summarizes current understanding of the role of IL28B in HCV infection and response to therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available